Dechra Pharmaceuticals Revenue vs. Return On Asset
| DPHAYDelisted Stock | USD 93.78 0.00 0.00% |
For Dechra Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Dechra Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Dechra Pharmaceuticals PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Dechra Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Dechra Pharmaceuticals PLC over time as well as its relative position and ranking within its peers.
Dechra |
Dechra Pharmaceuticals Return On Asset vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Dechra Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Dechra Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Dechra Pharmaceuticals PLC is rated as one of the top companies in revenue category among its peers. It also is one of the top stocks in return on asset category among its peers . The ratio of Revenue to Return On Asset for Dechra Pharmaceuticals PLC is about 14,263,598,326 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Dechra Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Dechra Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Dechra Revenue vs. Competition
Dechra Pharmaceuticals PLC is rated as one of the top companies in revenue category among its peers. Market size based on revenue of Drug Manufacturers—General industry is currently estimated at about 527.91 Billion. Dechra Pharmaceuticals adds roughly 681.8 Million in revenue claiming only tiny portion of equities under Drug Manufacturers—General industry.
Dechra Return On Asset vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Dechra Pharmaceuticals |
| = | 681.8 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Dechra Pharmaceuticals |
| = | 0.0478 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Dechra Return On Asset Comparison
Dechra Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Dechra Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Dechra Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Dechra Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Dechra Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Dechra Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom. Dechra Pharmaceuticals operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 1699 people.
Dechra Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Dechra Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Dechra Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Dechra Pharmaceuticals' important profitability drivers and their relationship over time.
Use Dechra Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dechra Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dechra Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Dechra Pharmaceuticals Pair Trading
Dechra Pharmaceuticals PLC Pair Trading Analysis
The ability to find closely correlated positions to Dechra Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dechra Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dechra Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dechra Pharmaceuticals PLC to buy it.
The correlation of Dechra Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dechra Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dechra Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dechra Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Dechra Pharmaceuticals position
In addition to having Dechra Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sport Products Thematic Idea Now
Sport Products
Companies manufacturing sporting goods and accessories. The Sport Products theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sport Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Dechra Pink Sheet
If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |